Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | ABSI |
---|---|---|
09:32 ET | 22137 | 2.89 |
09:33 ET | 3742 | 2.885 |
09:35 ET | 8607 | 2.87 |
09:37 ET | 6508 | 2.875 |
09:39 ET | 650 | 2.8775 |
09:42 ET | 403 | 2.8797 |
09:44 ET | 2782 | 2.875 |
09:46 ET | 100 | 2.8775 |
09:48 ET | 704 | 2.8779 |
09:50 ET | 1804 | 2.875 |
09:51 ET | 800 | 2.875 |
09:53 ET | 4300 | 2.8775 |
09:55 ET | 100 | 2.8799 |
09:57 ET | 1300 | 2.87 |
10:00 ET | 5910 | 2.875 |
10:02 ET | 1683 | 2.875 |
10:04 ET | 1933 | 2.875 |
10:06 ET | 2843 | 2.875 |
10:08 ET | 100 | 2.875 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Absci Corp | 322.5M | -3.1x | --- |
Lyell Immunopharma Inc | 323.5M | -1.4x | --- |
XOMA Royalty Corp | 353.6M | -9.8x | --- |
Design Therapeutics Inc | 328.4M | -6.6x | --- |
Jasper Therapeutics Inc | 308.6M | -4.2x | --- |
enGene Holdings Inc | 337.4M | -1.7x | --- |
Absci Corporation is a generative artificial intelligence (AI) drug creation company. The Company combines AI with scalable wet lab technologies to create biologics for patients. It has built an Integrated Drug Creation platform to identify novel drug targets, discover biotherapeutic candidates, and generate the cell lines to manufacture them in a single process. The Company uses its platform to predict, identify, design, construct, screen, select and scale production of biologic drug candidates for its partners, and learn from the data it generates. Its SoluPro technology is a multiplex synthetic biology approach that overcomes the limitations of highest-throughput automation labs. The Company supports its generative AI designs with its wet lab's high-throughput functional validation capabilities. It reconstructs prevalent immune-response molecules, such as antibodies from disease tissue and identify their corresponding antigens, offering new therapeutic targets.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $322.5M |
---|---|
Revenue (TTM) | $4.2M |
Shares Outstanding | 113.6M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 2.12 |
EPS | $-0.94 |
Book Value | $1.89 |
P/E Ratio | -3.1x |
Price/Sales (TTM) | 76.7 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -2,468.58% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.